ANIK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 105909 min ago

@ $23.63

Išleistas: 14 vas. 2024 @ 16:30

Grąža: 8.21%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 0.60 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	35 968.00
Vidutinė apimtis	80 309.00
Rinkos kapitalizacija	379.71M
EPS	$0 ( 2024-03-13 )
Kita pelno data	( $-0.190 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.53
ATR14	$0.0420 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Levitz Michael L	Buy	51 682	Stock Option (Right to Buy)
2024-03-15	Levitz Michael L	Buy	21 329	Restricted Stock Unit
2024-03-15	Colleran David	Buy	46 875	Stock Option (Right to Buy)
2024-03-15	Colleran David	Buy	19 345	Restricted Stock Unit
2024-03-15	Nunes Anne	Buy	26 442	Stock Option (Right to Buy)

INSIDER POWER
51.59
Last 100 transactions
Buy: 1 044 875 \| Sell: 338 384

Tūris Koreliacija

Ilgas: 0.02 (neutral)

Trumpas: 0.45 (neutral)

Signal:(45.096) Neutral

Anika Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RMRM	0.905
BPTH	0.892
GOODN	0.886
RMGC	0.883
MLVF	0.875
BCOV	0.872
ALLT	0.87
WISH	0.868
GOODO	0.868
APTX	0.868

10 Labiausiai neigiamai susiję koreliacijos
PTRS	-0.908
AAON	-0.874
ULBI	-0.866
CORT	-0.859
PXI	-0.855
STEP	-0.842
PSCE	-0.84
TUR	-0.838
GSHD	-0.837
FTXN	-0.837

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Anika Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.08
( neutral )

0.07
( neutral )

0.00
( neutral )

-0.15
( neutral )

-0.20
( neutral )

0.24
( neutral )

Anika Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$166.66M
Bruto pelnas:	$103.09M (61.85 %)
EPS:	$-5.64

FY	2023
Pajamos:	$166.66M
Bruto pelnas:	$103.09M (61.85 %)
EPS:	$-5.64

FY	2022
Pajamos:	$156.24M
Bruto pelnas:	$93.58M (59.89 %)
EPS:	$-1.020

FY	2021
Pajamos:	$147.79M
Bruto pelnas:	$82.94M (56.12 %)
EPS:	$0.290

Financial Reports:

No articles found.

Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.